EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients

Busyamas Chewaskulyong iD, Pattarapong Satjaritanun, Thanika Ketpueak, Thatthan Suksombooncharoen, Chaiyut Charoentum, Nuttaphoom Nuchpong, Apichat Tantraworasin iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0310781 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Busyamas Chewaskulyong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine, Chiang Mai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to assess the seroconversion rate and percent inhibition of neutralizing antibodies against the wild-type and Omicron variants of SARS-CoV-2 in patients with solid cancer who received two COVID-19 vaccine doses by comparing chemotherapy and nonchemotherapy groups.

Methods

This prospective cohort study enrolled 115 cancer patients from Maharaj Nakorn Chiang Mai Hospital, Sriphat Medical Center, Faculty of Medicine, Chiang Mai University, and Chiang Mai Klaimor Hospital, Chiang Mai, Thailand, between August 2021 and February 2022, with data from 91 patients who received two COVID-19 vaccine doses analyzed. Participants received vaccines as part of their personal vaccination programs, including various mRNA and non-mRNA vaccine combinations. Blood samples were collected at baseline, on day 28, and at 6 months post-second dose to assess neutralizing antibodies. The primary outcome was the seroconversion rate against the wild-type and Omicron variants on day 28. Secondary outcomes included seroconversion at 6 months, factors associated with seroconversion, and safety.

Results

Among the participants, 45% were receiving chemotherapy. On day 28, seroconversion rates were 77% and 62% for the wild-type and Omicron variants, respectively. Chemotherapy did not significantly affect seroconversion rates (p = 0.789 for wild type, p = 0.597 for Omicron). The vaccine type administered was positively correlated with seroconversion, with an adjusted odds ratio (95% confidence interval) of 25.86 (1.39–478.06) for the wild type and 17.38 (3.65–82.66) for the Omicron variant with the primary heterologous vaccine regimen. Grades 1 and 2 adverse events were observed in 34.0% and 19.7% of participants, respectively.

Conclusions

Despite the lower seroconversion rate against the Omicron variant, no significant difference was observed between the chemotherapy and nonchemotherapy groups. COVID-19 vaccinations demonstrated good tolerability in this cohort. These findings highlight the importance of vaccine safety and immunogenicity in cancer patients and can inform tailored vaccination strategies for this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesSARS-CoV-2SeroconversionThailand

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Medical Oncology Outpatient Clinic, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Surgery, General Thoracic Unit, Faculty of Medicine, and Clinical Surgical Research Center, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: Busyamas Chewaskulyong, Apichat Tantraworasin

Förderung

  • Faculty of Medicine, Chiang Mai University

Zitieren

APA

Chewaskulyong, B., Satjaritanun, P., Ketpueak, T., Suksombooncharoen, T., Charoentum, C., Nuchpong, N., & Tantraworasin, A. (2024). Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0310781

Vancouver

Chewaskulyong B, Satjaritanun P, Ketpueak T, Suksombooncharoen T, Charoentum C, Nuchpong N, et al. Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0310781

BibTeX
@article{Chewaskulyong2024,
  author = {Chewaskulyong, Busyamas and Satjaritanun, Pattarapong and Ketpueak, Thanika and Suksombooncharoen, Thatthan and Charoentum, Chaiyut and Nuchpong, Nuttaphoom and Tantraworasin, Apichat},
  title = {Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0310781}
}
Kostenlos starten →